Insulet (PODD) traded up 0.6 % during a 24 hours period ending at 03:19 PM Central Europe on Monday 26th. One Insulet stock can currently be bought for about USD 150.5 on popular exchanges. Current supply of Insulet stocks is 69.4 mn. Insulet has a current market capitalization of USD 10.3 bn and approximately USD 119.6 mn worth of Insulet was traded on exchanges in the last 24 hours. Since last month end, Insulet has traded 9.74 % up. Simple moving average of last 200 days is at USD 182.16. The highest price of past 52 weeks was recorded at USD 354.88 on 11/20/2025. 52 weeks low was at USD 126.4 on 08/05/2026.
Here is how related stocks have performed in the past 24 hours:
Summit Therapeutics (SMMT) traded down -0.51 % and now trades at USD 14.9. Current market capitalisation for Summit Therapeutics is USD 12.3 bn. Summit Therapeutics announced that its partner Akeso’s Phase III HARMONi‑GI1 trial has shown the investigational bispecific antibody ivonescimab combined with chemotherapy to provide a clinically meaningful improvement in overall survival compared with durvalumab plus chemotherapy in patients with advanced biliary tract cancer. The interim analysis reported a roughly 25 % reduction in the risk of death and statistically significant superiority for overall survival, alongside a favorable safety profile comparable to the control arm. The study, conducted exclusively in China, also met key secondary endpoints, demonstrating enhanced progression‑free survival, objective response, and disease‑control rates. Summit highlighted that this represents the first Phase III evidence of overall survival benefit in this disease setting and outlined plans for a registration‑enabling Phase II/III trial in the United States in collaboration with ECOG‑ACRIN, expected to begin in late 2026.
Antero (AR) traded up 2.87 % and now trades at USD 40.58. Antero has a market capitalisation of USD 12.4 bn. Current price/earnings ratio for Antero is 11.52.
Invesco (IVZ) traded down -2.54 % and now trades at USD 28.57. Invesco has a market capitalisation of USD 12.4 bn. In recent market commentary, several investment managers have highlighted the evolving dynamics of the technology and defence sectors. Analysts note that while some high‑beta technology stocks have receded, new opportunities are emerging among undervalued names, with a focus on deep research and selection. The AI and semiconductor subsectors remain of particular interest, as new product launches and supply‑chain developments continue to drive optimism. Simultaneously, defensive instruments such as dividend‑oriented funds and bond‑based products are gaining traction, reflecting a broader preference for balanced exposure in a market that has seen modest volatility. These trends suggest a cautious yet opportunistic stance, balancing growth potential in emerging technologies with risk‑managed defensive positioning.
Encompass Health (EHC) traded down -1.52 % and now trades at USD 125.91. Encompass Health has a market capitalisation of USD 12.2 bn. Encompass Health has a current price to earnings ratio of 20.7.
Tempus Ai (TEM) traded up 5.96 % and now trades at USD 65.72. Tempus Ai has a market capitalisation of USD 12.3 bn.
About Insulet
Insulet Corporation is a medical device company operating in the health care sector, specializing in health care equipment and supplies. The company develops, manufactures, and markets an insulin infusion system for people with insulin-dependent diabetes. Insulet Corp operates in the United Kingdom, Canada, and United States. You can find more information about the company and its products on its website, www.insulet.com , and it is listed on the Nasdaq stock exchange. The date of its Initial Public Offering (IPO) was 15th May 2007.
